STAG2 and breast carcinoma: PARP1 inhibitors have proven clinical efficacy for BRCA1/2‐mutated ovarian and breast cancers with deficient HR repair pathways.[35, 36, 37] In the present study, we demonstrated that depletion of STAG2 results in hypersensitivity to ATM inhibitors in cellular and animal models.